Amicus Therapeutics – A Biopharmaceutical Firm Based in New Jersey

Amicus Therapeutics is a biopharmaceutical firm based in New Jersey, America. The firm went public in 2007 under the trading name, NASDAQ (Google Finance). The establishment of Amicus Therapeutics was financed by selected capital venture firms such as Radius Venture, New Enterprise Associates, and Canaan Partners. The organization focuses on the treatment of rare and orphan diseases, more so lysosomal storage disorders. The product development of the company is primarily based on CHART (Chaperone-Advanced Replacement Therapy), as well as enzyme replacement therapies.
In 2014, Amicus Therapeutics was noted as one of the companies that have the broadest portfolio of pharmacological chaperones small molecule in the pharmaceutical industry. Moreover, Amicus Therapeutics has a robust development pipeline for the treatment of various human genetic disease. For example, Amicus Therapeutics has a lead product known as migalastat. The product is a personalized medicine that is used for treating people with Fabry disease. Amicus Therapeutics is also working in collaboration with JCR Pharmaceutical and GlaxoSmithKline to explore coformulation with the recombinant alpha-galactosidase. However, the collaboration lasted for only three years.
Amicus does not have the manufacturing capability to produce its products. It relies on contracts from other companies for the manufacturing process. However, in 2008, the company expanded its operation. Apart from the normal research site in New Jersey, Amicus Therapeutics also has another research site in San Diego. Since its establishment, Amicus has been on the good side of the business. In 2010, Amicus Therapeutics received a grant worth $500000 from Michael Joseph Fox Foundation. The grant was meant to support the research study that was being conducted by Amicus in partnership with David Geffen Medical School. The company also received another grant worth $210300 from ADDF (Alzheimer’s Drug Discovery Foundation). Amicus Therapeutics used the grant to support its pre-clinical work. Also, in 2013, Amicus was able to have the necessary intellectual property and proprietary materials for the treatment of Pompe infection.

For more information visit:

| Twitter


Make Any Day Valentine’s Day With Whitney Wolfe’s Bumble

Valentine’s day has passed and a lot of people have probably found themselves lamenting the fact that they did not have a valentine. Fortunately, it is not the end of the world. For one thing, there are plenty more valentine’s days left. Therefore, one can take the time to meet people who can potentially be romantic partners. This can be challenging. Fortunately, there are apps that can help with dating. Whitney Wolfe herself has developed an app for dating called Bumble. Bumble has made a lot of tweaks to the overall set up of dating apps. One of these has to do with who responds for dating.

Whitney Wolfe has made an adjustment that not only empowers women to go after what they want. At the same time, it makes it a little easier for men. One thing that men often complain about is that it is almost impossible for them to get a response on their dating profile. Bumble does something for the men in that it does not allow them to message, but makes it very urgent for the woman to message. One way that it accomplishes this is by showing the woman a match and only giving her a full day to respond. Otherwise, the match will disappear.

Click here to learn more about Whitney Wolfe.

Whitney Wolfe has made other apps that have made a huge revolutionary dent in the online dating industry. She was involved with the development of Tinder. However, Bumble is poised to pick up where Tinder left off when it comes to the innovations that are being brought to the dating industry. One of the goals she has is to match women up with someone who is right for her as soon as possible. While a good man is someone who is worth waiting for, it does not mean that the woman has to wait to find this good man. After all, life is short.